SOHM, Inc. Agrees to Licensing for Investigational and Pre-Clinical Studies for Groundbreaking ABBIE Genome Editing Technology for CAR-T Cell Cancer Therapies
Rhea-AI Summary
SOHM Inc (OTC PINK:SHMN) has announced a significant licensing agreement with an undisclosed drug development partner for its ABBIE genome editing technology focused on CAR-T cell cancer therapies. The company is set to receive $6 million in funding for advancing joint research initiatives.
The collaboration centers on SOHM's proprietary ABBIE (A Binding-based Integrase Enzyme) integration system, which aims to enhance the safe and efficient production of autologous CAR-T cells. The partnership combines SOHM's integration system with microfluidic gene editing capabilities to develop new micro-dosed CAR-T cell therapies for cancer treatment.
According to COO David Aguilar, PhD, this collaboration will position SOHM and its partners as leaders in microfluidic-based gene editing technology, potentially revolutionizing treatments for cancer and other diseases.
Positive
- Secured $6 million in potential funding through licensing agreement
- Expansion into CAR-T cell therapy market through strategic partnership
- Proprietary ABBIE technology shows commercial potential through licensing
Negative
- Partner remains undisclosed, creating uncertainty
- Funding is pending approval, not guaranteed
- Timeline for clinical implementation not specified
News Market Reaction
On the day this news was published, SHMN gained 11.11%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHINO HILLS, CA / ACCESS Newswire / April 28, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces today its collaboration and licensing agreement with an undisclosed emerging drug development partner. This partnership accentuates SOHM's leadership in gene editing and cell engineering.
David Aguilar, PhD, Chief Operating Officer, stated that this collaborative and licensing project will position SOHM and its partners as leaders in microfluidic-based gene editing technology to develop new micro-dosed CAR-T cell therapies to treat cancers. As part of this alliance, our partners are licensing SOHM's proprietary genome editing ABBIE products and methods. This partnership marks a significant leap forward in developing novel genome editing technologies and CAR-T-based therapies poised to revolutionize treatments for cancer and other diseases.
SOHM, Inc., is set to receive
David Aguilar, PhD, Chief Operating Officer, expressed his enthusiasm for the collaboration: "This partnership represents a pivotal moment in the pursuit of advanced genome editing technologies. By integrating our ABBIE system with microfluidic gene editing capabilities, we can accelerate research and bring innovative, cost-efficient micro-dosed CAR-T treatments to the clinic. Most importantly, our efforts will provide new hope for patients battling cancer."
The proposed project aims to streamline gene editing and CAR-T cell processes, making them more accessible and effective for therapeutic applications. By combining SOHM's proprietary integration system with our partners' cutting-edge technology under the license, the collaborators aspire to set new standards in the fields of CAR-T cell therapy and genome editing, significantly impacting the treatment of various diseases and improving overall patient care.
As advancements in genome editing and delivery systems continue to evolve, SOHM, Inc. and its partners are committed to leading the charge in transforming how genetic disorders, especially cancer, are approached. This collaboration signifies a crucial step towards integrating revolutionary technology into clinical practice, ultimately enhancing the future of biotechnology.
For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on ACCESS Newswire
FAQ
What is the value of SOHM's (SHMN) new licensing agreement for ABBIE technology?
How will SOHM's ABBIE technology be used in cancer treatment?
What is SOHM's (SHMN) ABBIE integration system?
What are the expected benefits of SHMN's new partnership in cancer therapy?
